文献速递神经肿瘤

伏昔尼布在治疗异柠檬酸脱氢酶突变型胶质瘤中的作用

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
PubMed 文献 · Neuro Oncol · 2025-01-01

本文综述伏昔尼布(一种脑渗透性突变IDH1/2小分子抑制剂)在IDH突变型胶质瘤治疗中的作用,讨论其融入日常实践的路线图、正在进行的单药或联合其他治疗的临床试验,以及当前挑战和未来方向。

要点

  • IDH突变型胶质瘤是年轻成人最常见的恶性原发性脑肿瘤,现有手术、放疗和化疗可改善生存但影响认知、生活质量等。
  • FDA近期批准伏昔尼布用于IDH突变型胶质瘤,预示治疗格局转变。
  • 综述提供伏昔尼布融入日常实践的路线图,并讨论正在进行的临床试验和未来方向。

核心结论

  • FDA近期批准伏昔尼布预示IDH突变型胶质瘤治疗格局的转变,本综述提供其融入日常实践的路线图。

研究设计与样本

  • 综述,讨论伏昔尼布在IDH突变型胶质瘤治疗中的作用、正在进行的临床试验及当前挑战和未来方向。

主要发现

  • IDH突变型胶质瘤是年轻成人最常见的恶性原发性脑肿瘤,给患者和照护者带来沉重负担,表现为神经认知缺陷和高死亡率。
  • 手术、放疗和化疗虽改善生存,但可能对认知功能、生活质量、经济、就业状态和整体独立性产生不良影响。
  • 伏昔尼布是一种脑渗透性小分子,靶向突变IDH1/2蛋白。

临床怎么用

  • 本综述提供伏昔尼布融入日常实践的路线图。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. de la Fuente MI, Touat M, van den Bent MJ, et al. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2025. PMID: 39723472. doi:10.1093/neuonc/noae259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。